Trial Profile
Phase II Study of Venetoclax Added to Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed by Consolidation With Cladribine Plus LDAC Alternating With 5-Azacitidine With Venetoclax in Patients With Untreated AML
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cladribine (Primary) ; Cytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results of subgroup analysis (From Nov 2018-Apr 2023, n=124 pts ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=123)of update of pts treated with CLAD, low dose cytarabine (LDAC) and Ven, focusing on outcomes and risk group stratification, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Oct 2023 Planned End Date changed from 1 Jun 2023 to 30 Apr 2025.